scholarly journals A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

2003 ◽  
Vol 349 (5) ◽  
pp. 427-434 ◽  
Author(s):  
James C. Yang ◽  
Leah Haworth ◽  
Richard M. Sherry ◽  
Patrick Hwu ◽  
Douglas J. Schwartzentruber ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Randomized Trial ◽  
Renal Cancer ◽  
Vascular Endothelial ◽  
Metastatic Renal Cancer ◽  
Endothelial Growth Factor

A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer

2014 ◽  
Vol 50 (12) ◽  
pp. 2057-2064 ◽  
Author(s):  
Thomas Powles ◽  
Shah-Jalal Sarker Foreshew ◽  
Jonathan Shamash ◽  
Naveed Sarwar ◽  
Simon Crabb ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Cancer ◽  
Clear Cell ◽  
Vascular Endothelial ◽  
Phase Ib ◽  
Endothelial Growth Factor ◽  
Cell Renal Cancer

The expression of RUNX3 gene in renal cell cancer and its clinical relevance with serum vascular endothelial growth factor

2017 ◽  
Vol 2 (2) ◽  
pp. 73
Author(s):  
Kalpesh Mahesh Parmar ◽  
Mamta Singla ◽  
Arup Kumar Mandal ◽  
Shalmoli Bhattacharya ◽  
Sharwan Kumar Singh
Keyword(s):  
Gene Expression ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Renal Cancer ◽  
Tumor Tissue ◽  
Cell Cancer ◽  
Vascular Endothelial ◽  
Runx3 Gene ◽  
Endothelial Growth Factor

<p>Background: Latest advances indicate that RUNX3 is a candidate tumor suppressor in several types of human cancers, including renal cell cancer.<br />However, its definitive role is not yet established. Vascular endothelial growth factor (VEGF) has been widely studied as a surrogate marker of<br />angiogenic activity and prognostic marker in renal cancer for monitoring treatment response and detection of early relapse. The aim of the study was<br />to examine the clinical significance of RUNX3 expression and serum VEFG in series of renal cancer patients using quantitative real-time polymerase<br />chain reaction and standard enzyme-linked immunosorbent assay kit and find its correlation with renal cancer stage, grade, and histopathology.<br />Materials and Methods: We reviewed our prospectively collected renal cancer database of 47 patients. All patients were evaluated preoperatively<br />and staged and underwent partial or radical nephrectomy as per the feasibility criteria. RUNX 3 expression in tumor tissue and adjoining parenchyma<br />was sampled in all patients, and serum levels of VEGF were measured in pre-and post-operative period on day 7 and day 30 after surgery. 10<br />age- and sex-matched healthy volunteers served as control group. Results: We observed that RUNX3 gene expression was significantly lower in<br />tumor tissue than in normal renal parenchyma of a renal cancer patient. The serum VEGF levels were significantly increased in patients with renal<br />cell carcinoma (RCC) compared to normal healthy volunteers and showed decreasing trend after the surgery. Loss of RUNX3 gene expression<br />and higher VEGF levels strongly correlated with high-grade tumors; however, it was not related to tumor size and histopathology. There was no<br />correlation of RUNX 3 with VEGF levels in RCC patients. Conclusion: The results of this study showed that renal cancer patients had increased<br />VEGF levels which were effectively alleviated by curative resection. Lower expression of RUNX3 in renal cancer suggests its tumor suppressive<br />role and new insights into targeted therapies linking RUNX3 gene may have some diagnostic and therapeutic implications in RCC patients. We did<br />not find any correlation between RUNX3 gene and serum VEGF.</p>

Vascular endothelial growth factor platelet counts, and prognosis in renal cancer

The Lancet ◽  
1999 ◽  
Vol 353 (9163) ◽  
pp. 1494-1495 ◽  
Author(s):  
Adrian L Harris ◽  
Kenneth J O'Byrne ◽  
Nicola Dobbs ◽  
David Propper ◽  
Kenneth Smith
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Cancer ◽  
Vascular Endothelial ◽  
Platelet Counts ◽  
Endothelial Growth Factor

PLASMA AND SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AS PROGNOSTIC FACTORS IN RENAL CANCER: A PROSPECTIVE ANALYSIS IN 367 PATIENTS

2009 ◽  
Vol 181 (4S) ◽  
pp. 212-212
Author(s):  
Gregory Verhoest ◽  
Marc Denis ◽  
Selim Zerrouki ◽  
Nathalie Rioux-Leclercq ◽  
Karim Bensalah ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Prognostic Factors ◽  
Growth Factor ◽  
Renal Cancer ◽  
Prospective Analysis ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Vascular endothelial growth factor and its type 2 receptor in tumors and serum of patients with renal cancer

2008 ◽  
Vol 145 (6) ◽  
pp. 744-747 ◽  
Author(s):  
N. E. Kushlinsky ◽  
M. F. Trapeznikova ◽  
E. S. Gershtein ◽  
P. A. Glibin ◽  
I. A. Kazantceva ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Renal Cancer ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document